Cryoport, Inc. (ticker: CYRX) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of CYRX's SEC filings surfaces 9 active risk signals, including 7 late-filing signals, 1 auditor-change signal, and 1 delisting/deregistration signal. CYRX reported $47.80M in revenue and -$10.54M for the period ending 2026-03-31, with operating cash flow of $3.73M. Cash and equivalents stood at $272.91M (up 655.9% year-over-year). Total assets of $763.61M exceed total liabilities of $268.62M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
CYRX SEC Filings
Full cached SEC EDGAR filing history for CYRX, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.